Terray Therapeutics

Research on the record

• 2026-10-15Terray and NVIDIA fine-tune a Nemotron model to read chemical reaction diagrams, setting a new best on the RxnCaption benchmarkLevel 2 · Computed
• 2026-06-11Terray's TerraSynth designs molecules with a route to make them, and in Terray's own projects chemists made half its compounds in 4 weeks instead of 8Level 4 · Tested in the physical world
• 2026-02-08Terray's TerraBind, a coarse-structure model, beats Boltz-2 by about 20% on binding-affinity correlation and runs 26x fasterLevel 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

Read on AI4S.fyi

• 2026-10-08Chasing the Grail: A History of Binding Affinity Predictions in Drug DiscoveryCommentaryDaniel Ramirez · Inside Valence

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2024-10Series B · $120MconfirmedLed by Bedford Ridge Capital, NVentures (NVIDIA) · With Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, Alexandria Venture InvestmentsStated use: take internal programs into clinical trials; improve tNova
• 2022-02-15Series A · $60MconfirmedLed by Madrona Venture Group · With Two Sigma Ventures, Digitalis Ventures, KdT Ventures, Goldcrest Capital, XTX Ventures, Alexandria Venture Investments, Sahsen Ventures, Greentrail CapitalStated use: advance the tNova platform
• 2022-02-15date disclosed · close date not givenSeed · $20MconfirmedLed by Digitalis Ventures, Two Sigma Ventures

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →